IL-37 is a unique member of the IL-1 family of cytokines, which functions as a natural suppressor of inflammatory and immune responses. Immune and non-immune cells produce IL-37 precursor following pro-inflammatory stimuli. Following activating cleavage by caspase-1, mature IL-37 translocates to the nucleus, where it suppresses transcription of pro-inflammatory genes. Both precursor and mature IL-37 are also secreted in the extracellular space, where they bind IL-18Rα and recruit the IL-1R8
| INTRODUCTION
Human IL-37 is a recently characterized member of the IL-1 family, which is unique in that it curbs inflammation by dampening production of pro-inflammatory cytokines. IL-37 was first discovered in silico in 2000, but its anti-inflammatory properties emerged only in recent years. A growing number of studies documented and confirmed a critical role in limiting excessive inflammatory responses and in preventing runaway inflammation, chiefly by suppressing innate inflammation but also by modulating acquired immunity. Thereby, similar to the anti-inflammatory cytokines IL-10 and transforming growth factor-β (TGF-β), IL-37 is captivating great interest from a biological as well as translational perspective.
The anti-inflammatory properties of IL-37 were first revealed by studies in which transfection of human IL-37 into mouse macrophages resulted in suppression of TLR-induced pro-inflammatory cytokines. 1 Instead, reducing endogenous IL-37 in human blood macrophages led to increased production of cytokines following IL-1 stimulation or engagement of Toll-like receptors (TLR). 1 However, unlike other members of the IL-1 family, a homologue gene for IL-37 has not been identified in the mouse. Therefore, it was not possible to generate IL-37-deficient mice, as is routinely performed when investigating the function of a new cytokine. Nevertheless, transgenic mice expressing the human IL-37 gene were generated (IL-37-transgenic, IL37-tg), and have extensively revealed the anti-inflammatory properties of this molecule. Specifically, IL37-tg mice are protected from a variety of pro-inflammatory stimuli or conditions, including endotoxemia, spinal cord injury, colitis, obesity and metabolic syndrome, and myocardial
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ischemia. [1] [2] [3] [4] [5] [6] Subsequently, these protective effects of IL-37 were confirmed by treatment with administration of exogenous, recombinant IL-37 in wildtype (WT) mice subjected to endotoxemia, acute lung and spinal cord injury, asthma, and myocardial infarction. [6] [7] [8] [9] [10] [11] [12] Studies also demonstrated that treatment of wildtype mice with recombinant human IL-37 is effective in inflammatory arthritis, 12 and revealed a property of IL-37 to induce metabolic reprogramming and to limit metabolic costs of inflammation, thus ameliorating inflammationinduced fatigue. 13 In addition, emerging evidence indicates that some effects of IL-37 also extend to indirectly limit acquired immunity. For example, IL37-tg mice exhibit reduced T cell responses to antigenspecific challenges. 14 In humans, production of IL-37 is activated by pro-inflammatory stimuli, including cytokines, as a protective mechanism to prevent runaway inflammation and excessive tissue damage. Accordingly, IL-37 levels are altered in patients with different inflammatory and autoimmune diseases. Research is moving toward development of IL-37
as a therapeutic for inflammatory diseases. However, despite fervent interest in this novel, non-canonical cytokine, some aspects of IL-37
biology and the exact role in human disease remain undetermined.
Studies investigating this natural regulator of innate immunity may prove critical to the understanding of rampant inflammation, such as that characterizing auto-inflammatory diseases. Equally important is to develop a clinical use of IL-37 to treat human disease.
| In silico discovery of IL-37
Three research groups independently reported preliminary identification of IL-37. [15] [16] [17] As shown in Figure 1 , five transcripts for the human IL37 gene have been identified (IL-37a-e); however, differences in specific activity and relative abundance of each remain as yet undetermined. IL-37b is the most complete of these isoforms, and includes 5 of the 6 exons of the IL37 gene (all but exon 3). Exons 4, 5, and 6 encode for the sequence required for the beta-fold barrel structure and account for the extracellular activity of recombinant IL-37.
Conversely, exons 1, 2, and 3 may be cleaved in the extracellular environment by unknown proteases. IL-37 isoforms a, b and d share exons 4, 5, and 6, and encode functional proteins. The IL-37 isoforms c and e lack one or more of these exons and likely encode non-functional proteins. IL-37b is also the most abundant and studied, as nearly all published investigations focused on this isoform.
The gene encoding IL-37 is found on chromosome 2q12-13 as part of the large IL-1 gene cluster, in remarkably close proximity to the regulatory regions for IL-1α and IL-1β genes. 18 This specific location is likely critical to the role of IL-37 as a master regulator of inflammatory responses: when transcription of IL-1α and IL-1β genes is induced by pro-inflammatory challenges, IL-37 is also simultaneously transcribed and limits the detrimental consequences of rampant inflammation.
This can be observed, for example, in human blood monocytes and macrophages stimulated with LPS. 18 As mentioned, no mouse gene homologue to human IL37 has been identified. Specifically, the first exon of IL-37 is present in the mouse but there is no open reading frame. Divergent evolutionary pathways due to selective pressure from different pathogens may account for the absence of a functional homolog of human IL37 in mice. Unexpectedly, neither has a gene encoding IL-37 been identified in our closest genetic relative among upper apes, the chimpanzee;
however, IL-37 is present in the gorilla and in other primates. 19 One possible explanation to this inter-species variability is that an ancestral IL37 gene was disrupted by insertion of endogenous retroviruses, both in the mouse as well as in the chimpanzee. However, it is also theoretically possible that other IL-37 exons remain unidentified in these species. 
| PRODUCTION, PROCESSING, AND RELEASE OF IL-37

| Production of IL-37
| Processing and release of IL-37
IL-37 is produced following pro-inflammatory stimuli. Accordingly, serum levels of IL-37 are particularly low in healthy humans (<100 pg/mL), but have been reported to rise in patients with inflammatory diseases such as rheumatoid arthritis, 21 lupus 10 and pre-eclampsia, 22 probably in attempt to dampen ongoing inflammation. The production, processing and release of IL-37 are shown in Figure 2 . In vitro, IL-37 precursor is actively produced in endotoxinstimulated human blood monocytes and can be observed by Western blotting. 23 However, similar to other members of the IL-1 family, the IL-37 precursor contains no classical signal peptide at the N-terminus prompting translocation to secretory pathways. ; however, this can be ascribed to increased secretion of IL-37 precursor rather than processed IL-37. 23 In general, most of secreted IL-37 found in the extracellular space is unprocessed and in the precursor form.
The IL-37 precursor released in the extracellular space is biologically active in vivo and in vitro. 
| RECEPTORS AND MECHANISM OF ACTION
As shown in Figure 
| Receptor complex: IL-18Rα and IL-1R8
Early studies reported that IL-37 binds to the alpha chain of the IL-18
receptor (IL-18Rα). 17, 24 Since this receptor was known for transducing the pro-inflammatory effects of IL-18, it was initially postulated that IL-37 might function as a receptor antagonist for IL-18Rα. However, this hypothesis was subsequently challenged by observations that IL-37 binds IL-18Rα with very low affinity, and that treatment with incremental doses of recombinant IL-37 yielded no effects on IL-18-stimulated production of IFN-γ by NK cells, both findings inconsistent with being a receptor antagonist. 27 Also in contrast with the receptor antagonist hypothesis, it was later revealed that low concentrations, rather than high concentrations of recombinant IL-37, most effectively suppress cytokine production in vitro. 7, 8 IL-18 binds to its receptor IL-18Rα on the cell surface and recruits the IL-18Rβ chain. 28 The To univocally confirm the concept that IL-37 binds to IL-18Rα and recruits IL-1R8, specific binding has been demonstrated using different techniques, including immunofluorescence, immunoprecipitation, and proximity ligation assays. 
| IL-1R8 is required for the anti-inflammatory effects of IL-37
Multiple studies have demonstrated that IL-1R8 is required for the anti-inflammatory effects of recombinant IL-37. For example, the anti-inflammatory effects of recombinant IL-37 are abrogated in primary macrophages and DCs from mice lacking IL-1R8, 5, 7 as the reduction in LPS-induced TNF-α and IL-6 upon IL-37 treatment was not observed in cells from IL-1R8-deficient mice. 7 Also, whereas macrophages transfected with IL37 exhibit up to 83% reductions in IL-1β production compared with wildtype macrophages, this reduction is decreased to 34% when IL-1R8 is silenced. 5 Since IL-37 forms a complex with IL-18Rα and IL-1R8, it is not unexpected that a comparable attenuation of the IL-37 effects could be observed upon silencing of IL-18Rα. 5 In vivo studies confirm that IL-37 requires IL-1R8 to exert antiinflammatory effects. For example, the beneficial effects of treatment with recombinant IL-37 on joint and systemic inflammation are nearly abrogated in mice deficient for this receptor. 12, 13 The protection afforded by IL-37 treatment against inflammatory injury in pulmonary aspergillosis was also not observed in mice deficient in IL-1R8. 8 Additional evidence comes from genetic crossing of IL37-tg mice with mice deficient in IL-1R8. While IL37-tg mice are protected from LPSinduced shock, in IL37-tg mice deficient in IL-1R8 there is a near total loss of this protection, 5 a finding paralleled at the cellular level with loss of the effects of IL-37 on cytokine production, transcription factors, and signaling kinases. 5 Regulation of IL-1R8 expression is therefore highly relevant for the anti-inflammatory effects of IL-37. In a study evaluating gene expression in the inflamed synovia of patients with rheumatoid arthritis, IL-37 was scarcely expressed, whilst expression of IL-1R8 was upregulated.
This clinical reality points at a therapeutic potential for administration of IL-37 in humans: while levels of endogenous IL-37 are likely too low to limit the runaway inflammatory reaction in the rheumatoid synovia, exogenous administration may restore immune homeostasis and suppress joint inflammation. Environmental conditions also affect IL-1R8
expression. For example, expression of IL-1R8 tends to decrease with age in rats, but levels can be increased and restored to near baseline levels in rats subjected to caloric restriction. 
| Interactions of extracellular IL-37 with the IL-18 Binding Protein
In the extracellular space, IL-18 binds to the IL-18 Binding Protein (IL-18BP) with a markedly high affinity of 0.5 nM. 40, 41 Moreover, IL-18BP circulates in health at 2-4 ng/mL whereas IL-18 is present at less than 200 pg/mL. 42 Thus, there is little free IL-18 in health, 43 while most of the IL-18BP is free. IL-18BP sequesters soluble IL-18
and prevents binding to the receptor, thus inhibiting IL-18-induced IFNγ production. However, these anti-inflammatory properties of IL-18BP are lost with increasing dosing. 44 Since IL-18BP in the extracellular space also binds to IL-37, 27 a novel concept for inflammation is that with increasing levels of IL-18BP there is less IL-37 to promote anti-inflammatory effects. This concept is clinically relevant since IL-18BP is presently being used as a therapeutic agent for humans with inflammatory conditions such as Adult Onset Still's Disease and in patients with mutations in NLRC4. 40, 45 IL-18BP is also a possible treatment for Macrophage Activation Syndrome, 46 rheumatoid arthritis or plaque psoriasis. 47 However, high dosing of IL-18BP may reduce its anti-inflammatory efficacy due to neutralization of endogenous IL-37.
The same mechanism is unlikely in the mouse, as no homologue gene for human IL37 has been identified.
| Dimerization of IL-37b at high concentrations
A consistent finding is that recombinant IL-37 exerts its potent anti-inflammatory effects at very low concentrations. Specifically, optimal reduction in LPS-induced IL-1β, IL-6, and TNF-α in cultured human PBMC occurs when IL-37 is present in the picomolar range. 7 In vivo, doses of 1 μg or 100 ng per mouse are effective. 8, 12, 13 In contrast, the same recombinant forms and concentrations of IL-37 exhibited either no suppression or paradoxically increased cytokines in vitro. The explanation for the low-dosing effectiveness of IL-37
can be due to the spontaneous formation of homodimers of IL-37.
On SDS reducing gels, western blotting of LPS-stimulated PBMC reveals two molecular weights: the monomer at 22 kDa and a dimer at 42 kDa. 1 Dimer formation was identified over a decade ago. 24 More recently, the crystallization of IL-37 using recombinant IL-37
46-218 has been reported 48 : in that study, two mutants 46-218 with D73K exchange and 46-218 with Y85A exchange were identified as being monomers. When injected into mice, there was an increase in the suppression of LPS-induced plasma IL-6 compared to wildtype IL-37 (46-218). 48 In whole blood assays, in cultured PBMC and upon transfection into THP-1 cells, the monomeric variants of IL-37 also exhibited increased activity at high concentrations (100 ng/mL). Conversely, the dimer-forming wildtype IL-37 (46- How much of the biologic activity of IL-37 in suppressing inflammation is due to nuclear or extracellular IL-37 remains to be determined.
Studies aimed at elucidating the relative contribution of exogenous or endogenous forms of IL-37, both in IL37-tg mice as well as in humans, hold clear translational relevance, in that they may guide very different approaches for the development or exploitation of IL-37 as a therapeutic agent.
| Requirement for Smad3
Unlike 
| EFFECTS OF IL-37
| Role of endogenous IL-37
The capacity of IL-37 to suppress innate inflammation was initially IL-37 also boosted IL-6, IL-1β, and TNF-α production in human blood monocytes stimulated with LPS. 7 These early studies delineated the concept that endogenous IL-37 functions as a mechanism to limit cytokine production.
| Suppression of cytokines, transcription factors, and signaling kinases
In human monocyte/macrophage cell lines, expression of IL-37 modulates the activation status of various signaling phosphokinases and generally tilts the balance towards anti-inflammatory pathways. 
| Effects of recombinant IL-37
The anti-inflammatory effects of IL-37 have been extensively 17 is more active than the originator IL-37b precursor. 7 Recombinant IL-37a with the N-terminus at lysine 27 is also active. 54 Clearly, the identification of the amino acid sequence affording the most potent anti-inflammatory effects holds translational relevance for development of IL-37 as a therapeutic. This property of IL-37, that is, suppression of mTOR and activation of AMPK, represents a reversal of the Warburg effect. In a recent study, administration of recombinant IL-37 to mice subjected to inflammation-induced fatigue increased exercise tolerance by inducing metabolic reprogramming via activation of AMPK: consistent with a reversal of the Warburg effect, these effects were associated with increased rates of oxidative phosphorylation in mitochondria of treated animals. 13 These studies substantiate the concept that, besides prominent anti-inflammatory effects, IL-37 also induces complex effects on metabolism.
| Impact on cell energy metabolism and reversal of the Warburg effect
| PROTECTIVE EFFECTS OF IL-37 IN DISEASE MODELS
In IL37-tg mice, the full-length precursor cDNA of IL37b isoform with a CMV promoter is inserted into embryos. 1 IL37-tg mice breed normally and exhibit no obviously altered phenotype. Although expression of IL-37 is unremarkable under physiologic circumstances, IL37-tg mice are protected from a broad variety of pro-inflammatory stimuli. These protective effects of IL-37 were initially documented in models of endotoxemia induced by LPS administration, and revealed by significantly reduced levels of circulating cytokines, hypothermia, acidosis, hyperkalemia, hepatitis, and dehydration. 1 Some of the disease models revealing the protective effects of IL-37, either in IL37-tg mice or in mice treated with recombinant IL-37 or administered IL-37-expressing plasmids, are described hereby.
| Experimental colitis
Dextran sulfate sodium (DSS) induced colitis is a chemically induced mouse model of inflammatory colitis, which is widely used because of its simplicity and histologic similarities with human ulcerative colitis. When IL37-tg mice were subjected to colitis, clinical and histological disease scores were significantly reduced, leukocyte recruitment into the colonic lamina propria was diminished, and ex vivo release of IL-1β and TNF-α from colon tissue explants was considerably lower compared to wildtype animals. 2 These effects were associated with an increase in the production of anti-inflammatory mediator IL-10. However, since an IL-10 receptor-blocking antibody did not reverse the observed antiinflammatory effects, protection against colitis in IL37-tg appears to be independent of IL-10. In the same study, wildtype mice receiving bone marrow cells from IL37-tg mice also exhibited protection against colitis, thus suggesting that myeloid cells expressing IL-37 provided the protection. 
| Spinal cord injury
In humans, accidents resulting in traumatic injuries to the spinal cord are associated with various degrees of motor impairment or limb paralysis. In experimental models, localized lesions result in spinal cord tissue damage and impaired motor function. IL37-tg mice subjected to spinal cord injury were protected against the development of motor disability and exhibited greater mobility compared to wildtype counterparts. 6 The clinical improvement was paralleled by decreased infiltration of neutrophils and monocytes, reduced microglia activation, and reduced production of pro-inflammatory cytokines into the injured spinal cord tissue. 
| Metabolic syndrome
The role of IL-18, IL-1β and, particularly, caspase-1 is central to the development of metabolic syndrome and type 2 diabetes.
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The protective effects of IL-37 against these complications of obesity were tested in IL37-tg mice fed a high-fat diet for 16 weeks.
IL37-tg mice exhibited reduced lipid accumulation in the liver, improved response to insulin, increased glucose tolerance, and fewer macrophages infiltrating the adipose tissue compared to wildtype mice 4 ; also of note, IL37-tg mice gained less weight despite equal caloric intake. 4 These effects in IL37-tg mice were associated with increased serum levels of the adipokine adiponectin. Adiponectin is an anti-inflammatory cytokine produced by adipocytes, which is known to foster insulin sensitivity. These effects of IL-37 on fat tissue homeostasis were confirmed in human subjects, as IL-37 mRNA baseline levels in subcutaneous adipose tissue were positively associated with lower adipose tissue leptin, lower inflammatory status of the adipose tissue, and functionally appropriate insulin responses. 4 Thus, IL-37 in human adipose tissue mitigates inflammation and the detrimental consequences of obesity and metabolic syndrome.
| Aging, tissue inflammation, and cancer genesis
Increased baseline inflammation is a feature of aging organisms and tissues. Based on the observation that incidence of some B-cell cancers such as lymphoma peaks in elderly patients, researchers compared various functions of bone marrow B-cell progenitors in old wild type mice, young wildtype mice, and age-matched IL 37-tg mice.
Interestingly, bone marrow B-cell progenitors of 20-month-old wildtype mice exhibited several defects compared to younger counterparts, particularly in signaling pathways, gene expression, and cell metabolism. However, bone marrow B-cell progenitor functions in 20-month-old IL37-tg mice were preserved at levels similar to young wildtype mice; in addition, IL37-tg mice were protected from the development of virus-induced leukemia. 58 Since a chronic inflammatory bone marrow microenvironment renders B-cell progenitor populations particularly susceptible to oncogenesis in the elderly, 58 IL-37 expression in this scenario confers protection against oncogenesis by inducing an anti-inflammatory microenvironment in the aging bone marrow.
| Inflammatory arthritis
The therapeutic potential of exogenous administration of IL-37 was In addition to these studies in sensitized mice, DCs isolated from the spleen of IL37-tg mice not subjected to antigen sensitization also exhibited a drastic reduction (75%-89%) in the cell surface expression of CD86 and MHC class II molecules. 1 Similar changes in cell surface markers were observed in human DCs exposed to recombinant IL-37. 10, 59 These data indicate that modulation of innate inflammation by IL-37 also impacts upon acquired immunity.
IL-37 may also directly affect the functionality of acquired immune responses, specifically fostering the immunosuppressive activity of regulatory T cells. In a study of human regulatory T cells (CD4 + CD25 + ), IL-37 expression was increased and associated with increased TGF-β levels. 62 Functional relevance of endogenous IL-37 was demonstrated by specific silencing, and revealed by reduced FOXP3 and CTLA-4 expression and TGF-β and IL-10 production. 62 Reducing endogenous IL-37 in regulatory T cells also resulted in increased IL-2 production and impaired capacity to suppress proliferation of effector T cells. 8 In a different study, DCs from IL37-tg mice subjected to skin sensitization exhibited increased production of IL-10. 14 In IL 37-tg mice subjected to a model of inflammatory colitis, there was also an increase in IL-10 production by colon tissue; however, the protective effects of IL-37 were shown to be IL-10-independent, as antibody blockade of the IL-10 receptor did not abrogate the effects. In mice subjected to inflammatory arthritis, the efficacy of treatment with recombinant IL-37 was also unrelated to induction of IL-10. 12 In all probability, these cytokines act in concert to regulate human immune responses through specific and distinct anti-inflammatory properties.
| ROLE OF IL-3IN INFLAMMATORY HUMAN DISEASE
Levels of IL-37 can be either increased or decreased in human disease.
Increased levels of IL-37 have been reported across several human conditions, by measuring mRNA levels in circulating cells and in affected tissue, as well as by assessing the concentrations of IL-37 in the serum or plasma. In addition, immunohistochemistry analyses and production from cells in vitro are also reported.
IL-37 is expressed in colon tissue samples from patients with inflammatory bowel disease but not healthy subjects. 64, 65 Other conditions characterized by elevated levels of IL-37 include psoriasis, systemic lupus erythematosus, chronic obstructive pulmonary disease, coronary artery disease, and hepatitis C or B infection. These and similar studies support the concept that chronic infection or inflammation increase IL-37 expression, which is an appropriate response to limit disease severity. Accordingly, other anti-inflammatory mediators such as IL-1 receptor antagonist, soluble TNF-α receptors, and the IL-18BP are also elevated in several of the diseases listed in Table 1 .
Some studies on rheumatoid arthritis report elevated IL-37 levels in the serum, 21, 66 but gene expression studies on the diseased synovia indicate that IL-37 is not particularly expressed, consistent with clinical findings of inflamed joints. 12 A study in the Chinese population report that patients carrying a mutation in the coding region of IL37 have lower disease activity scores and less pain, thus indicating a gain of function for the anti-inflammatory effects of IL-37.
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In other diseases, elevated levels of IL-37 can be interpreted in two ways, either as an appropriate response to limit inflammation, or as a detrimental factor contributing to disease. For example, baseline IL-37 expression is remarkably higher in PBMCs from HIV-1-infected subjects compared to controls, and correlates with the levels of soluble CD14. 68 These elevated levels of IL-37 may limit inflammation associated with chronic HIV-1 infection, or may directly contribute to immunosuppression. 68 In contrast, lower levels of IL-37 compared to healthy subjects characterize patients with a wide range of inflammatory diseases (Table 1) . This clinical situation is more easily interpreted as inadequate levels of IL-37 to limit ongoing inflammation, and reflect a failure to induce sufficient levels to mitigate disease severity.
Genetic studies also point at a role for IL- 
